Using mRNA Isoforms to Classify Prostate Cancer
Author Information
Author(s): Zhang Chaolin, Li Hai-Ri, Fan Jian-Bing, Wang-Rodriguez Jessica, Downs Tracy, Fu Xiang-Dong, Zhang Michael Q
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
Can profiling alternatively spliced mRNA isoforms improve prostate cancer classification compared to overall mRNA profiling?
Conclusion
Profiling of splice isoforms provides unique and important information that enhances prostate cancer classification.
Supporting Evidence
- 464 splice isoforms from more than 200 genes are differentially regulated in tumors.
- A support vector machine classifier trained on 128 signature isoforms can correctly predict 92% of the cases.
- Isoform profiling provides about 30% more information than conventional microarrays.
Takeaway
This study looks at different versions of genes to help tell if someone has prostate cancer, and it finds that these versions can give better clues than just looking at the total amount of genes.
Methodology
The study used a DASL assay to profile mRNA splice isoforms in prostate cancer tissues and applied support vector machine classifiers for analysis.
Potential Biases
Potential biases may arise from the selection of genes and the methodology used for profiling.
Limitations
The study's findings are based on a limited sample size and may not generalize to all prostate cancer cases.
Participant Demographics
The study included 22 cases of prostate tumors and 16 matched normal samples.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website